Dopamine D3 receptor agonists partially reproduce the discriminative stimulus effects of cocaine in squirrel monkeys

RD Spealman

Harvard Medical School, New England Regional Primate Research Center, Southborough, Massachusetts, USA.

Dopamine agonists and antagonists varying in affinity and selectivity at the D3 subtype of D2-like receptors were studied in squirrel monkeys trained to discriminate cocaine from vehicle in a two-lever choice procedure. In drug substitution experiments, all dopamine agonists engendered dose-related increases in the percentage of cocaine-lever responses, reaching average maxima of 61 to 85%. The order of potency of the drugs for engendering cocaine-like stimulus effects [(+)-4- propyl-9-hydroxynaphthoxazine > (R)-(-)-propylnorapomorphine > (+/-)-2- dipropylamino-7-hydroxy-1,2,3,4-tetrahydronaphthalene > or = PD 128907 > or = quinpirole > bromocriptine] approximated their reported order of potency in both functional (agonist-stimulated mitogenesis) and radioligand ([125I]iodosulpiride) binding assays in cells expressing cloned human D3 receptors but not in cells expressing cloned human D2 or D4 receptors. In antagonism studies, the cocaine-like stimulus effects of the most selective of the D3 agonists, PD 128907, were attenuated by D2-like receptor antagonists with an order of potency (nemonapride > eticlopride > YM-43611) that correspondence more closely to their reported order of affinity at cloned human D3 than either D2 or D4 receptors. The effects of PD 128907 were not attenuated by the D1- like receptor antagonist SCH 39166. In a final series of experiments, the discriminative stimulus effects of cocaine were enhanced in a largely additive manner by PD 128907, (+/-)-2-dipropylamino-7-hydroxy- 1,2,3,4-tetrahydronaphthalene and quinpirole. The results support a role for D3 receptor mechanisms in the cocaine-like stimulus effects of D3-preferring agonists and suggest the similar mechanisms may contribute to the effects of cocaine.

Volume 278, Issue 3, pp. 1128-1137, 09/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				J. M. Witkin, B. Levant, A. Zapata, R. Kaminski, and M. Gasior The Dopamine D3/D2 Agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] Protects against Acute and Cocaine-Kindled Seizures in Mice: Further Evidence for the Involvement of D3 Receptors J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 930 - 938. [Abstract] [Full Text] [PDF]

				I. Gyertyan, B. Kiss, K. Gal, I. Laszlovszky, A. Horvath, L. I. Gemesi, K. Saghy, G. Pasztor, M. Zajer, M. Kapas, et al. Effects of RGH-237 [N-{4-[4-(3-Aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an Orally Active, Selective Dopamine D3 Receptor Partial Agonist in Animal Models of Cocaine Abuse J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1268 - 1278. [Abstract] [Full Text] [PDF]

				P. W. Czoty, C. R. Ramanathan, N. H. Mutschler, A. Makriyannis, and J. Bergman Drug Discrimination in Methamphetamine-Trained Monkeys: Effects of Monoamine Transporter Inhibitors J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 720 - 727. [Abstract] [Full Text] [PDF]

				J. M. Witkin, D. Dijkstra, B. Levant, H. C. Akunne, A. Zapata, S. Peters, H. E. Shannon, and M. Gasior Protection against Cocaine Toxicity in Mice by the Dopamine D3/D2 Agonist R-(+)-trans-3,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907] J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 957 - 964. [Abstract] [Full Text] [PDF]

				M. Gasior, C. A. Paronis, and J. Bergman Modification by Dopaminergic Drugs of Choice Behavior under Concurrent Schedules of Intravenous Saline and Food Delivery in Monkeys J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 249 - 259. [Abstract] [Full Text] [PDF]

				S. R. Vorel, C. R. Ashby Jr, M. Paul, X. Liu, R. Hayes, J. J. Hagan, D. N. Middlemiss, G. Stemp, and E. L. Gardner Dopamine D3 Receptor Antagonism Inhibits Cocaine-Seeking and Cocaine-Enhanced Brain Reward in Rats J. Neurosci., November 1, 2002; 22(21): 9595 - 9603. [Abstract] [Full Text] [PDF]

				S. B. Caine, S. S. Negus, N. K. Mello, S. Patel, L. Bristow, J. Kulagowski, D. Vallone, A. Saiardi, and E. Borrelli Role of Dopamine D2-like Receptors in Cocaine Self-Administration: Studies with D2 Receptor Mutant Mice and Novel D2 Receptor Antagonists J. Neurosci., April 1, 2002; 22(7): 2977 - 2988. [Abstract] [Full Text] [PDF]

				T. V. Khroyan, R. L. Barrett-Larimore, J. K. Rowlett, and R. D. Spealman Dopamine D1- and D2-Like Receptor Mechanisms in Relapse to Cocaine-Seeking Behavior: Effects of Selective Antagonists and Agonists J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 680 - 687. [Abstract] [Full Text]

				V. Audinot, A. Newman-Tancredi, A. Gobert, J.-M. Rivet, M. Brocco, F. Lejeune, L. Gluck, I. Desposte, K. Bervoets, A. Dekeyne, et al. A Comparative In Vitro and In Vivo Pharmacological Characterization of the Novel Dopamine D3 Receptor Antagonists (+)-S 14297, Nafadotride, GR 103,691 and U 99194 J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 187 - 197. [Abstract] [Full Text]

				B. Geter-Douglass, J. L. Katz, K. Alling, J. B. Acri, and J. M. Witkin Characterization of Unconditioned Behavioral Effects of Dopamine D3/D2 Receptor Agonists J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 7 - 15. [Abstract] [Full Text]